Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022… Read more
Pharma Equity Group A/S Cl A (PEG) - Net Assets
Latest net assets as of June 2025: Dkr39.38 Million DKK
Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) has net assets worth Dkr39.38 Million DKK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr62.30 Million) and total liabilities (Dkr22.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr39.38 Million |
| % of Total Assets | 63.21% |
| Annual Growth Rate | -0.87% |
| 5-Year Change | 42.57% |
| 10-Year Change | -50.9% |
| Growth Volatility | 103.49 |
Pharma Equity Group A/S Cl A - Net Assets Trend (2008–2024)
This chart illustrates how Pharma Equity Group A/S Cl A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharma Equity Group A/S Cl A (2008–2024)
The table below shows the annual net assets of Pharma Equity Group A/S Cl A from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | Dkr48.88 Million | +92.93% |
| 2023-09-30 | Dkr25.33 Million | -44.98% |
| 2022-09-30 | Dkr46.05 Million | +8.17% |
| 2021-09-30 | Dkr42.57 Million | +24.17% |
| 2020-09-30 | Dkr34.28 Million | -48.95% |
| 2019-09-30 | Dkr67.16 Million | -13.43% |
| 2018-09-30 | Dkr77.57 Million | -8.84% |
| 2017-09-30 | Dkr85.09 Million | -12.08% |
| 2016-09-30 | Dkr96.78 Million | -2.77% |
| 2015-09-30 | Dkr99.53 Million | +1.62% |
| 2014-09-30 | Dkr97.95 Million | +192.90% |
| 2013-09-30 | Dkr-105.44 Million | -389.77% |
| 2012-09-30 | Dkr36.39 Million | -54.33% |
| 2011-09-30 | Dkr79.67 Million | +50.13% |
| 2010-09-30 | Dkr53.06 Million | -0.76% |
| 2009-09-30 | Dkr53.47 Million | -4.95% |
| 2008-09-30 | Dkr56.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharma Equity Group A/S Cl A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6657900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Dkr122.76 Million | 251.16% |
| Total Equity | Dkr48.88 Million | 100.00% |
Pharma Equity Group A/S Cl A Competitors by Market Cap
The table below lists competitors of Pharma Equity Group A/S Cl A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
2invest AG
XETRA:2INV
|
$13.67 Million |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3
|
$13.68 Million |
|
Hercules Investments Limited
NSE:HERCULES
|
$13.70 Million |
|
Carbonxt Group Ltd
AU:CG1
|
$13.71 Million |
|
Plus Group Holdings Inc.
F:EJ0
|
$13.66 Million |
|
Chin Huay PCL
BK:CH
|
$13.66 Million |
|
Steel Hawk Berhad
KLSE:0320
|
$13.66 Million |
|
Bayview Acquisition Corp Class A Ordinary Shares
NASDAQ:BAYA
|
$13.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharma Equity Group A/S Cl A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,333,000 to 48,875,000, a change of 23,542,000 (92.9%).
- Net loss of 24,422,000 reduced equity.
- Other comprehensive income increased equity by 984,033,000.
- Other factors decreased equity by 936,069,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-24.42 Million | -49.97% |
| Other Comprehensive Income | Dkr984.03 Million | +2013.37% |
| Other Changes | Dkr-936.07 Million | -1915.23% |
| Total Change | Dkr- | 92.93% |
Book Value vs Market Value Analysis
This analysis compares Pharma Equity Group A/S Cl A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.85x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-09-30 | Dkr66.77 | Dkr0.08 | x |
| 2009-09-30 | Dkr55.03 | Dkr0.08 | x |
| 2010-09-30 | Dkr60.03 | Dkr0.08 | x |
| 2011-09-30 | Dkr46.29 | Dkr0.08 | x |
| 2012-09-30 | Dkr20.64 | Dkr0.08 | x |
| 2013-09-30 | Dkr-69.55 | Dkr0.08 | x |
| 2014-09-30 | Dkr49.41 | Dkr0.08 | x |
| 2015-09-30 | Dkr4.37 | Dkr0.08 | x |
| 2016-09-30 | Dkr4.98 | Dkr0.08 | x |
| 2017-09-30 | Dkr3.83 | Dkr0.08 | x |
| 2018-09-30 | Dkr3.26 | Dkr0.08 | x |
| 2019-09-30 | Dkr0.33 | Dkr0.08 | x |
| 2020-09-30 | Dkr1.08 | Dkr0.08 | x |
| 2021-09-30 | Dkr0.77 | Dkr0.08 | x |
| 2022-09-30 | Dkr1.04 | Dkr0.08 | x |
| 2023-09-30 | Dkr0.02 | Dkr0.08 | x |
| 2024-09-30 | Dkr0.05 | Dkr0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharma Equity Group A/S Cl A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.34x
- Recent ROE (-49.97%) is below the historical average (-35.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -164.74% | 0.00% | 0.00x | 4.65x | Dkr-98.29 Million |
| 2009 | -25.74% | 0.00% | 0.00x | 1.62x | Dkr-16.71 Million |
| 2010 | -2.67% | -273.69% | 0.00x | 9.37x | Dkr-6.72 Million |
| 2011 | -21.31% | -109.63% | 0.03x | 6.37x | Dkr-24.94 Million |
| 2012 | -118.94% | -326.58% | 0.03x | 13.85x | Dkr-46.92 Million |
| 2013 | 0.00% | -287.29% | 0.20x | 0.00x | Dkr-131.28 Million |
| 2014 | -6.07% | -4492.42% | 0.00x | 1.27x | Dkr-15.70 Million |
| 2015 | -2.92% | -447.26% | 0.00x | 1.33x | Dkr-12.26 Million |
| 2016 | -1.11% | -98.20% | 0.01x | 1.35x | Dkr-10.35 Million |
| 2017 | 0.21% | 0.00% | 0.00x | 1.01x | Dkr-8.33 Million |
| 2018 | -9.94% | 0.00% | 0.00x | 1.04x | Dkr-15.47 Million |
| 2019 | -21.47% | 0.00% | 0.00x | 1.20x | Dkr-21.13 Million |
| 2020 | -95.90% | 0.00% | 0.00x | 1.68x | Dkr-36.30 Million |
| 2021 | 12.67% | 0.00% | 0.00x | 1.50x | Dkr1.14 Million |
| 2022 | 7.56% | 0.00% | 0.00x | 1.54x | Dkr-1.13 Million |
| 2023 | -97.14% | 0.00% | 0.00x | 2.67x | Dkr-27.14 Million |
| 2024 | -49.97% | 0.00% | 0.00x | 1.34x | Dkr-29.31 Million |
Industry Comparison
This section compares Pharma Equity Group A/S Cl A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,674,000
- Average return on equity (ROE) among peers: -3346.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharma Equity Group A/S Cl A (PEG) | Dkr39.38 Million | -164.74% | 0.58x | $13.66 Million |
| Gubra A/S (GUBRA) | $80.01 Million | 15.86% | 1.44x | $338.83 Million |
| STRAP (STRAP) | $9.34 Million | -6708.84% | 17.55x | $1.48 Million |